Nancy Lurker - 06 Jan 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
CEO, Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
06 Jan 2023
Net transactions value
$0
Form type
4
Filing time
10 Jan 2023, 16:58:13 UTC
Previous filing
02 Mar 2022
Next filing
13 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Award $0 +450,800 $0.000000 450,800 06 Jan 2023 Common Stock 450,800 $3.26 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option to purchase will vest and become exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.